EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 267 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily April 28, 2021 Metformin May Affect Risk of Breast Cancer in Women with Type... January 28, 2021 Commemorating the Contributions of Cancer Research Greats March 12, 2021 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Load more HOT NEWS Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... How to Keep Your Loved One With Cancer Safe From Infection... 6 highlights from our Black in Cancer conference Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs
